Anzeige
Mehr »
Login
Donnerstag, 09.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 920892 | ISIN: US9706461053 | Ticker-Symbol: WIJ
Frankfurt
09.01.25
08:02 Uhr
202,00 Euro
0,00
0,00 %
1-Jahres-Chart
WILLIS LEASE FINANCE CORPORATION Chart 1 Jahr
5-Tage-Chart
WILLIS LEASE FINANCE CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
200,00210,0011:24
202,00210,0008:00
GlobeNewswire (Europe)
200 Leser
Artikel bewerten:
(1)

Willis Lease Finance Corp.: Willis Aviation Services Limited Selected by Jet2.com for Expert MRO Services in UK

Finanznachrichten News

Third Largest Airline in the UK Partners with Willis to Ensure Continued Fleet Reliability

COCONUT CREEK, Fla., Jan. 08, 2025(NASDAQ: WLFC) ("WLFC" or the "Company"), the leading lessor of commercial aircraft engines and global provider of aviation services, announces its subsidiary, Willis Aviation Services Limited ("WASL"), a leading aircraft maintenance, repair and overhaul ("MRO") provider, has entered into a long-term General Terms Agreement ("GTA") and volume commitment with leading leisure airline Jet2.com ("Jet2") to perform C Checks on Jet2's B737NG aircraft.

Leveraging its expertise and advanced capabilities, WASL will deliver these heavy base maintenance services at its growing state-of-the-art facility at Teesside International Airport in Northeastern England. This strategic collaboration underscores Jet2's commitment to ensuring the highest standards of safety, reliability, and superior performance across its aircraft operations.

"We're excited to partner with Jet2.com, a respected airline known for its customer focus and operational excellence," said Austin C. Willis, WLFC's Chief Executive Officer. "This agreement highlights our commitment to delivering premier MRO solutions while supporting Jet2's fleet, fostering local economic growth and creating skilled jobs in the UK aerospace industry."

"At Jet2, safety and reliability are at the heart of everything we do," said Chris Hubbard, Director of Engineering & Maintenance at Jet2.com. "We are confident that Willis Aviation Services Limited's proven capability and commitment to quality will ensure our fleet continues to meet the highest standards, enabling us to continue delivering an exceptional experience to our customers."

Willis Lease Finance Corporation
Willis Lease Finance Corporation ("WLFC") leases large and regional spare commercial aircraft engines, auxiliary power units and aircraft to airlines, aircraft engine manufacturers and maintenance, repair, and overhaul providers worldwide. These leasing activities are integrated with engine and aircraft trading, engine lease pools and asset management services through Willis Asset Management Limited, as well as various end-of-life solutions for engines and aviation materials provided through Willis Aeronautical Services, Inc. Through Willis Engine Repair Center®, Jet Centre by Willis, and Willis Aviation Services Limited, the Company's service offerings include Part 145 engine maintenance, aircraft line and base maintenance, aircraft disassembly, parking and storage, airport FBO and ground and cargo handling services.

Except for historical information, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties. Do not unduly rely on forward-looking statements, which give only expectations about the future and are not guarantees. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which the forward-looking statement is based, except as required by law. Our actual results may differ materially from the results discussed in forward-looking statements. Factors that might cause such a difference include, but are not limited to: the effects on the airline industry and the global economy of events such as war, terrorist activity and the COVID-19 pandemic; changes in oil prices, rising inflation and other disruptions to world markets; trends in the airline industry and our ability to capitalize on those trends, including growth rates of markets and other economic factors; risks associated with owning and leasing jet engines and aircraft; our ability to successfully negotiate equipment purchases, sales and leases, to collect outstanding amounts due and to control costs and expenses; changes in interest rates and availability of capital, both to us and our customers; our ability to continue to meet changing customer demands; regulatory changes affecting airline operations, aircraft maintenance, accounting standards and taxes; the market value of engines and other assets in our portfolio; and risks detailed in the Company's Annual Report on Form 10-K and other continuing and current reports filed with the Securities and Exchange Commission. It is advisable, however, to consult any further disclosures the Company makes on related subjects in such filings. These statements constitute the Company's cautionary statements under the Private Securities Litigation Reform Act of 1995.

CONTACT:Lynn Mailliard Kohler
Manager Corporate Communications
(415) 328-4798


A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/516a02a3-6597-404b-9d51-2ce757dd77ad


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.